Eye Keratitis and conjunctivitis, viral eye infections, eye redness. Gastrointestinal Dental discomfort and pain, gastrointestinal signs and symptoms, gastrointestinal infections, gastroenteritis, gastrointestinal disorders, oral ulcerations, oral erythema and rashes, constipation, appendicitis, oral discomfort and pain. Hepatobiliary Tract and Pancreas Abnormal liver function tests. Lower Respiratory Lower respiratory signs and symptoms, pneumonia, lower respiratory infections. Musculoskeletal Arthralgia and articular rheumatism; muscle stiffness, tightness, and rigidity; bone and cartilage disorders. Neurology Sleep disorders, tremors, hypnagogic effects, compressed nerve syndromes. Non-Site Specific Allergies and allergic reactions, congestion, viral infections, pain, chest symptoms, fluid retention, bacterial infections, wheeze and hives, unusual taste. Skin Viral skin infections, urticaria, skin flakiness and acquired ichthyosis, disorders of sweat and sebum, sweating. The incidence of common adverse events reported in Study 3, a 28-week, non-US clinical study of 503 patients previously treated with inhaled corticosteroids who were treated twice daily with ADVAIR DISKUS 500/50, fluticasone propionate inhalation powder 500 mcg and salmeterol inhalation powder 50 mcg used concurrently, or fluticasone propionate inhalation powder 500 mcg was similar to the incidences reported in Table 3. Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis: The incidence of common adverse events in Table 4 is based upon 1 placebo-controlled, 24-week, US clinical trial in patients with COPD associated with chronic bronchitis. A total of 723 adult patients (266 females and 457 males) were treated twice daily with ADVAIR DISKUS 250/50, fluticasone propionate inhalation powder 250 mcg, salmeterol inhalation powder 50 mcg, or placebo. | ||||
Email this article
Printer friendly
Bookmark this pageadvertisement
